anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a water-in-oil emulsified-type cosmetic made by emulsification using an emulsifier, particularly with a silicone-containing oil emulsified, and improved in emulsion stability.  <P>SOLUTION: The emulsified-type cosmetic emulsified with an emulsifier is provided. This cosmetic is such as to be compounded with hydrophilic-and-hydrophobic anisotropic plate-like particles comprising such plate-like acrylic polymer particles that, when the contact angles of the respective one surface A and the other surface B with water at 20°C are measured, the contact angle difference between both the surfaces is ≥15°. This type of cosmetic, which is obtained by emulsifying a silicone oil-containing oil with a silicone-based surfactant, is suitable to its emulsion stability. In this cosmetic, the hydrophilic-and-hydrophobic anisotropic plate-like particles include such plate-like particles of an acrylic copolymer where the hydrophilic groups are arranged on the one surface and hydrophobic groups arranged on the other surface, or of a mixture of such acrylic copolymers.  <P>COPYRIGHT: (C)2011,JPO&INPIT
This is a Phase 2/3 study, with Part 1A (Blinded Phase), Part 1B (Open-label Observational Phase), Part 1C (Booster Dose \[BD\] Phase), which consists of Part 1C-1 and Part 1C-2, Part 2 (Open-Label), and Part 3 (Open-label). Participants in Part 1A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part 1B of the study is designed to offer participants whose age group becomes Emergency Use Authorization (EUA) eligible to be unblinded so that participants who received placebo in Part 1A can request 2 doses of open-label mRNA-1273 vaccine. Part 1C-1 of the study will offer participants in Part 1A and Part 1B who are at least 5 months from the last dose, the option to request a homologous BD of mRNA-1273. Part 1C-2 is designed to provide a heterologous BD of mRNA-1273 to eligible participants who completed primary COVID-19 vaccination series with a non-Moderna vaccine under EUA and are at least 3 months from the last dose. Part 2 is an open-label design. Participants will receive 2 doses and may receive a booster dose of mRNA-1273 SARS-CoV-2 vaccine. Part 3 is an open-label design. Participants will receive up to 2 doses of mRNA-1273.222 vaccine.

Please access http://TeenCoveStudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.
Impaired basic academic skills (e.g., word recognition) are common in children with Attention Deficit Hyperactivity Disorder (ADHD). The underlying neuropsychological and neural correlates of impaired Chinese reading skills in children with ADHD have not been substantially explored. Three hundred and two children with ADHD (all medication-naïve) and 105 healthy controls underwent the Chinese language skill assessment, and 175 also underwent fMRI scans (84 ADHD and 91 controls). Between-group and mediation analyses were applied to explore the interrelationships of the diagnosis of ADHD, cognitive dysfunction, and impaired reading skills. Five ADHD-related brain functional networks, including the default mode network (DMN) and the dorsal attention network (DAN), were built using predefined regions of interest. Voxel-based group-wise comparisons were performed. The ADHD group performed worse than the control group in word-level reading ability tests, with lower scores in Chinese character recognition (CR) and word chains (WS) (all P < 0.05). With full-scale IQ and sustained attention in the mediation model, the direct effect of ADHD status on the CR score became insignificant (P = 0.066). The underlying neural correlates for the orthographic knowledge (OT) and CR differed between the ADHD and the control group. The ADHD group tended to recruit more DMN regions to maintain their reading performance, while the control group seemed to utilize more DAN regions. Children with ADHD generally presented impaired word-level reading skills, which might be caused by impaired sustained attention and lower IQ. According to the brain functional results, we infer that ADHD children might utilize a different strategy to maintain their orthographic knowledge and character recognition performance.
For best results, use tc99m from a generator eluted within 24 hours. The eluate should be used within 2 hours of elution.

Reconstitution Instructions:

  1. Snap off the plastic lid and place in appropriate lead shielding. Wipe the septum with 70% isopropyl alcohol and allow it to dry.
  2. Using a 10 mL syringe, draw up 100 mCi of tc99m (in approximately 2 mL) and inject into the ECD Buffer, being sure to withdraw an equal amount of gas from the vial to neutralize pressure.
  3. With a sterile syringe, inject 3 mL of 0.9% sodium chloride into the reaction vial to dissolve the contents. Remove an equal volume of air to maintain pressure within the vial. Shake the contents of the vial for a few seconds.
  4. With another sterile syringe, immediately (within 30 seconds) withdraw 1 mL out of the reaction vial and inject it into the buffer vial. Discard the reaction vial
  5. Swirl the contents of the buffer vial for a few seconds and allow this mixture to stand for 30 minutes at room temperature.
  6. Examine the vial contents for particulates and discoloration prior to patient administration. It should be clear of any particulates.



It is recommended that the kit be stored refrigerated until use; at such time the product should be aseptically withdrawn
Group1 (low-dose group), 8 papatients are treated with 10 μg/mL GD-iExo-001. Group2 (high-dose group), 8 papatients are treated with 50 μg/mL GD-iExo-001. One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
Certain benzoyl chloride phenylhydrazones have been found to be active against insects and mites, and they have also been found to be effective, broad-spectrum anthelmintics for suppressing parasitic worms in animals, particularly sheep. The benzoyl ring and the phenylhydrazone ring can be substituted with a halogen atom, a nitro group, or an alkyl group of from 1 to 6 carbon atoms, inclusive. A new class of pentahalobenzoyl chloride phenylhydrazones is described, particularly pentafluorobenzoyl chloride phenylhydrazones. The compounds are prepared by reacting a benzoic acid phenylhydrazide with phosphorus pentachloride to obtain a benzoyl chloride (dichlorophosphinyl)phenylhydrazone that is reacted with phenol to produce the desired benzoyl chloride phenylhydrazones. Certain of the compounds can be prepared by direct chlorination of a benzaldehyde phenylhydrazone. Methods of using the new compounds and new anthelmintic formulations are described. The new compound p-toluoyl chloride phenylhydrazone is effective against worms at rates at least as low as 100 mg./kg. of body weight in sheep.
Nowadays shopping in supermarkets, malls, marts and other commercial places becomes a very important part of human life. Apart from just shopping, these places offer so many entertainment platforms for every age group of people under one roof. Therefore, to attract the customers, the shop owners are always trying to introduce unique flavour in their shopping platforms, such as: Digital Payment methods, Automatic controlling systems, location indicator of the particular store, Smart Trolley and etc. Shopping Trolley is always hidden but a very crucial part of your shopping. Here, we are putting this hidden component into the central attraction for the shopping. In our proposed invention idea (Smart Trolley), we are planning to put so many customer friendly features into the trolley, which takes the customer's shopping experience into another level. In our proposed Smart Trolley system, we are planning to incorporate smart lock, smart pooling, product scanners, location indicator, weighing machine, e-payment system and product reminder/assistant. In the Covid-19 pandemic, technology has played a very important role in the smooth run of human life and it has also convinced the young as well as old people to make their life align with the recent advancements. With this emphasis, our invention, “Smart Trolley” will give the smart, safe and secure shopping experience to the customers as well as store owners too. Business retail's owners can also adapt the proposed system in their business platforms because the implementing cost will also be adjusted in the long run as the proposed system will help to reduce the supporting staff size.
Anxiety, fear and sleep disorders are frequently encountered conditions in preoperative patient evaluation. Common postoperative problems include pain, sleep disturbances, nausea and vomiting. When these problems are not dealt with effectively, patient comfort and satisfaction are adversely affected, recovery time after surgery and total hospital stay are prolonged, and the time allocated to nursing care increases. Today, it has gained great importance to try to manage these problems with pharmacological and non-pharmacological evidence-based approaches. In particular, nurses need to identify possible problems in both preoperative patient evaluation and postoperative patient follow-up and produce solutions for them. Although it is stated in studies that using easy, effective and safe non-invasive methods such as meditation and virtual reality can reduce the possibility of complications, increase the comfort level of patients, improve the quality of post-surgical recovery, and thus make the surgical process successful, there is no evidence to defend its effectiveness more clearly. more based studies are needed.
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
Prior to Iron treatment Investigator will sample subject blood for: counting blood, iron sector indices, renal function, electrolytes, and measure the level of ghrelin fasting plasma. In addition, the patient will fill a structured questionnaire that examines appetite levels. participants will be asked to answer a structured questionnaire which will include information on demographics, clinical data (fever, allergies, weight, height) and comorbidities. Additional data on laboratory tests, comorbidities, medication and regular blood and urine cultures results will be taken from the medical file. Iron treatment will be given according to local standard procedure . At the end of the treatment ghrelin levels and questionaire will be retaken .

iron deficiency anemia is defined: hemoglobin \<12 gr / dl in women and Hb \<13 gr / dl in men with ferritin \<15 ng / ml.
Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
Chromoendoscopy by applying a dye (indigo-carmine) through the colonoscop is the new standard for cancer surveillance in patients with IBD . It gives the opportunity to identify suspected areas of dysplasia and to take targeted biopsies. The diagnostic accuracy improves and the chances for detecting dysplastic areas increase. In recent years new endoscopic techniques have been developed, including laser-based endomicroscopy. There is an increasing need for structured evaluation of the efficiency of these techniques. Laser-based endomicroscopy, taking in vivo confocal microscopy pictures during the colonoscopy examination, is the most promising new method. This method is established in highly rated centers for the early diagnosis of neoplasia in the bile ducts and the esophagus but its role for detection early malignancies in the colon is not known and studying this issue is of very high clinical value.

Specific questions: Does the use of laser-based endomicroscopy increase the chances for early detection of dysplasia? What is the intraobserver variability? What is the learning curve for interpretation of confocal microscopy pictures? Material and methods: A laser-based endomicroscope (Cellvizio®, Mauna Kea Technologies) have been acquired and the examination procedure has been established at the Unit for Gastroenterology and Hepatology, Karolinska University Hospital Huddinge. Eighty patients with PSC and IBD included in annual surveillance with colonoscopy with routine biopsy regime will be included in the study. After informed consent, patients are investigated with laser-based endomicroscopy during surveillance colonoscopy. Each colonic segment will be examined before and after staining with indigo-carmin. After intra-venous fluorescein (FITC) injection, all macroscopically abnormal lesions will be examined by endomicroscopy. Intravenous administration of FITC makes it possible to obtain in vivo microscopic pictures with up to a 1000x magnification of the colon mucosa. The Cellvizio® technique allows for evaluation of epithelial and endothelial cell structures in areas with suspicious changes as well as for acquisition of directed biopsies. Confocal pictures from all sites where biopsies have been taken are saved for future blind re-evaluation. The biopsies are taken according to the routine standard with minimum of 2 biopsies from each 10 cm in the colon. For the immunological and microbiological (specific aim 2) parts of the study, additional 16 biopsies are gathered from left, transverse, and right colon. All the laser-based endomicroscopy pictures and sequences are saved for further evaluation and further application in arranging pedagogical sessions for evaluation of the learning curve of the technique.
The study was a randomized controlled trial, triple-blind, single-center/surgeon/assessor. The study was conducted between April 2019 to May 2021. We evaluated 30 patients (both genders) aged 20-55 years, having failed conservative treatment of unilateral HNP undergone for at least 6 weeks, with visual analogue scale (VAS) of greater than 30, and confirmed a single-level HNP, corelated to clinical, by MRI. The exclusion criteria included previous spine surgery or epidural injection, progressive neurological deficit, cauda equina, coagulopathy-related conditions, associated cervical myelopathy, systemic bone and joint diseases. All patients had to have been exempted from NSAIDs for at least one week. Patients were treated by transforaminal epidural injections. Fifteen patients were in triamcinolone and PRP groups each. PRP was obtained from 24 ml venous blood through standardized double-spin protocol. Participants were fifteen patients each in triamcinolone and PRP groups. The same postoperative protocols and medications were applied. The visual analogue scale of leg (LegVAS), collected at baseline, 2, 6, 12, and 24 weeks, was the primary outcome. The BackVAS, Oswestry Disability Index (ODI), adverse event, and treatment failure were the secondary endpoints. All subjects were analyzed according to the intention-to-treat principle. All statistical analyses were performed with STATA 17.
Sweating is a common and bothersome side effect of treatment with antidepressants. Most or all antidepressants have been clearly shown to cause excessive sweating. It is unclear to what extent excessive sweating caused by antidepressants becomes less or goes away with time. In many instances, it continues to be a problem even after 6 or more months on the antidepressant.

There is no generally accepted treatment for excessive sweating. This study has been designed to study whether terazosin is effective in reducing antidepressant-induced sweating, and whether it is well-tolerated and acceptable to patients. In addition, secondary objectives of this study are to determine the time taken for patients to respond to terazosin, the usual doses needed for improvement, and the extent of reduction in sweating. This information will not only help doctors in using terazosin for this purpose in their patients, but will help in designing further studies of this treatment.
Chronic diabetic wounds are a serious complication of diabetes and often result in limb amputations and confer high mortality rates. The proinflammatory secretome in the wound perpetuates defective neovascularization and contributes to dysregulated tissue repair. This study aims to design a gelatin methacrylamide (GelMA) hydrogel to sustained the release of grancalcin-neutralizing antibody (GCA-NAb) and evaluate it as a potential scaffold to promote diabetic wound healing. Results show that the expression of grancalcin(GCA), a protein secreted by bone marrow-derived immune cells, is elevated in the wound sites of individuals and animals with diabetic ulcers. Genetic inhibition of grancalcin expression accelerates vascularization and healing in an animal model. Mechanistic studies show that grancalcin binds to transient receptor potential melastatin 8(TRPM8) and partially inactivates its downstream signaling pathways, thereby impairing angiogenesis in vitro and ex vivo. Systemic or topical administration of a GCA-NAb accelerate wound repair in mice with diabetes. The data suggest that GCA is a potential therapeutic target for the treatment of diabetic ulcers.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic having protection effects and beautification effects on the skin and the hair by using algae of natural products as raw materials.  <P>SOLUTION: This cosmetic contains an alga protein, a peptide of a hydrolyzate thereof or a derivative such as an ester thereof in a usual skin cosmetic, hair cosmetic, bath medicine, or the like. Seaweeds such as Porphyra, Undaria pinnatifida, Chlorella pyrenoidosa and Spirulina are suitable as the algae, and the proteins are obtained from the algae by destroying the cell walls of the algae, e.g. by grinding, and extracting the protein therefrom with a solvent. The alga peptides are obtained by hydrolyzing the algae directly or hydrolyzing the proteins with an enzyme, an acid or an alkali, or by subjecting them to pressurized thermal extraction.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Teratogenic Effects: Pregnancy Category C:

There are no adequate and well-controlled studies of PROAIR HFA Inhalation Aerosol or albuterol sulfate in pregnant women. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients treated with albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established. Animal reproduction studies in mice and rabbits revealed evidence of teratogenicity. PROAIR HFA Inhalation Aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

In a mouse reproduction study, subcutaneously administered albuterol sulfate produced cleft palate formation in 5 of 111 (4.5%) fetuses at an exposure approximately eight-tenths of the maximum recommended human dose (MRHD) for adults on a mg/m2 basis and in 10 of 108 (9.3%) fetuses at approximately 8 times the MRHD. Similar effects were not observed at approximately one-thirteenth of the MRHD. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated subcutaneously with isoproterenol (positive control).

In a rabbit reproduction study, orally administered albuterol sulfate induced cranioschisis in 7 of 19 fetuses (37%) at approximately 630 times the MRHD. 

In a rat reproduction study, an albuterol sulfate/HFA-134a formulation administered by inhalation did not produce any teratogenic effects at exposures approximately 65 times the MRHD [see Nonclinical Toxicology (13.2)].
Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Hepatitis C virus (HCV) is a positive-sensed, single-stranded RNA virus that belong to the Flaviviridae family and Hepacivirus. World Health Organization(WHO) is estimated that there are more than 170 million, about 2.9% people infected by HCV in the world. About 80% of HCV infection results in chronic infection that can lead to severe liver diseases, such as cirrhosis and hepatocellular carcinoma. Recently, the combination therapy of peginterferon alpha-2a and ribavirin is recommended as a standard care for HCV infections in clinical, but chronic infection often leads to HCV can resistance interferon alpha-2a and escape the treatment. In clinical search, interferon alpha-2a and ribavirin had great side effects to patients, so we were eager to find drugs that have less side effects and good anti-viral effect to improve clinical treatment for HCV infection. In order to understand the pathway that HCV replicate in host cells, Scientists recently develop many type of cell lines that contain HCV subgenomic replicon system. A synthetic HCV subgenomic RNA has been replaced HCV structural protein region to the neomycin-phosphotransferase gene and encephalomyocarditis virus (EMCV) internal ribosome entry segment (IRES). HCV RNA 5'-untranslated region (UTR) is as an internal ribosomal entry site (IRES) and promoting HCV downstream gene, so that HCV replicon can be expressed from these special cell lines and has good expressed efficiency. we used the Ava.5 cell line that is expressed HCV1b replicon establish the platform for testing anti-HCV drugs, and studied the biochemical mechanism of anti-HCV drugs. First, we used MTS assay to measure cytotoxicity after the drugs treated cells. The treatment with the drugs at concentrations that did not induce cell death, and then we examined HCV subgenomic RNA by reverse transcription polymerase chain reaction and western blot to check the drugs whether inhibit HCV replication or not. Finally, we confirmed hypericin can inhibit HCV1b NS5A RNA and NS3 protein. In order to clarify the biochemical mechanisms that inhibit HCV replication, we combined treated hypericin and interferon alpha-2a for Ava.5 cells. In this study, we comfirm that there is no synergistic effect between hypericin and interferon alpha-2a to inhibit HCV1b NS3 protein. In the other hand, hypericin can inhibit Phospho- PKC α Thr638/β II Thr641, but interferon alpha-2a can't inhibit it. We think hypericin is different from the mechanism of interferon alpha-2a inhibited HCV NS3 protein. After treated Ca2+ -dependent PKC inhibitor Go 6976, HCV NS3 protein was inhibited by Go 6976 in Ava.5 cell line. According to this result, we expect that Ca2+ -dependent PKC signaling transduction regulated NS3 protein replicated. In our study, we comfirm that hypericin is a excellent pure compound to inhibit HCV replicon replicated in Ava.5 cells. In order to interferon alpha-2a has many side effects to HCV patients, we think that hypericin may be a good option to cure HCV patients in clinical. In the other hand, when the HCV patients resistance to IFN- α treatment, we have the option to cure the IFN- α resistanced HCV patients by hypericin.
The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells are provided. Recombinant PAV  viruses are obtained by transfection of mammalian cells with recombinant PAV  genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.